ICO logo

Iconovo AB (publ) Stock Price

OM:ICO Community·SEK 113.0m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author

ICO Share Price Performance

SEK 1.18
-1.22 (-50.84%)
SEK 1.18
-1.22 (-50.84%)
Price SEK 1.18

ICO Community Narratives

There are no narratives available yet.

Trending Discussion

Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet with slight risk.

4 Risks
1 Reward

Iconovo AB (publ) Key Details

SEK 14.5m

Revenue

SEK 3.0m

Cost of Revenue

SEK 11.5m

Gross Profit

SEK 54.9m

Other Expenses

-SEK 43.4m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
Apr 24, 2026
-0.45
79.26%
-298.40%
0%
View Full Analysis

About ICO

Founded
2013
Employees
19
CEO
Anders Mansson
WebsiteView website
www.iconovo.se

Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreement with Lonza to develop spray-dried formulations of an intranasal biologic drug; and agreement with Kiox Pharma to develop an inhalable treatment for interstitial lung disease. Iconovo AB (publ) was founded in 2013 and is headquartered in Lund, Sweden.

Recent ICO News & Updates

Recent updates

No updates